|
News For BMY;PPHM;PFE From The Last 14 Days Check below for free stories on BMY;PPHM;PFE the last two weeks. |
|
|
| May 22, 2013 |
| 16:00 EDT |  | BMY | Options Update; May 22, 2013
 Subscribe for More Information |
|
| 10:33 EDT |  | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
| |
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 08:50 EDT | | PPHM | Peregrine reaches agreement with FDA on Phase 3 trial design for Bavituximab
Peregrine Pharmaceuticals announced that it has reached agreement with the FDA on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer. The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. The Phase III clinical trial will be a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel alone enrolling approximately 600 patients at sites worldwide. The trial will enroll Stage IIIB/IV non-squamous, NSCLC patients who have progressed after standard front-line treatment. The primary endpoint of the trial will be overall survival. |
|
| 08:40 EDT | | PPHM | Peregrine trading halted, pending news
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
| |
|
|
|
|
